newsfilter
← Latest News
Business Wire·

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

  • Agenus Inc. will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026.
  • The company plans to host a stakeholder briefing webcast in late March to discuss strategic plans, data milestones, & updates on the botensilimab & balstilimab development programs.
  • Agenus is an immuno-oncology leader founded in 1994, headquartered in Lexington, MA, with capabilities in antibody therapeutics, adoptive cell therapies, & adjuvants.
  • Botensilimab (BOT) is an Fc-enhanced anti-CTLA-4 antibody designed to activate immune responses in "cold" tumors, with approximately 1,200 patients treated in phase 1 & 2 trials across nine metastatic cancer types.
  • Balstilimab (BAL) is a monoclonal IgG4 antibody blocking PD-1 interaction, evaluated in over 900 patients to date with demonstrated clinical activity & favorable tolerability.
  • The press release includes standard forward-looking statement warnings regarding risks, uncertainties, & regulatory timelines subject to the company's SEC filings.